The drug industry is deeply concerned about the Centre's move to control the prices of diabetes and cardiovascular medicines. The move to reduce the prices of these drugs would impact industry revenues worth Rs. 600-crore, Mr. S. V. Veerramani, President of Indian Drug Manufacturers Association (IDMA) was quoted as saying in a business newspaper report. However, the IDMA has sought the government to hold the move till the industry takes up a detailed study on the full impact.
展开▼
机译：药物工业对中心控制糖尿病和心血管药物价格的举动深表关注。降低这些药物价格的举措将影响价值卢比的行业收入。商业报纸的报道援引印度制药商协会（IDMA）主席S. V. Veerramani先生的话说，这是60亿卢比。但是，IDMA一直在寻求政府采取行动，直到该行业对整个影响进行详细研究为止。
展开▼
